Biogen Inc. (BIIB) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
BIIB Insider Trading Activity
BIIB Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $151,559 | 1 | 25 |
Sells | $1,419,454 | 3 | 75 |
Related Transactions
| DORSA CAROLINE | director | 1 | $151,559 | 0 | $0 | $151,559 |
| Singhal Priya | Head of Development | 0 | $0 | 2 | $105,312 | $-105,312 |
| SHERWIN STEPHEN A | director | 0 | $0 | 1 | $1.31M | $-1.31M |
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Biogen Inc.
Over the last 12 months, insiders at Biogen Inc. have bought $151,559 and sold $1.42M worth of Biogen Inc. stock.
On average, over the past 5 years, insiders at Biogen Inc. have bought $662,891 and sold $2.41M worth of stock each year.
Highest buying activity among insiders over the last 12 months: DORSA CAROLINE (director) — $151,559.
The last purchase of 1,235 shares for transaction amount of $151,559 was made by DORSA CAROLINE (director) on 2025‑05‑02.
List of Insider Buy and Sell Transactions, Biogen Inc.
| 2025-05-02 | DORSA CAROLINE | director | 1,235 0.0008% | $122.72 | $151,559 | -2.85% | ||
| 2025-03-07 | Sale | SHERWIN STEPHEN A | director | 8,760 0.0059% | $150.02 | $1.31M | -18.59% | |
| 2024-12-09 | Sale | Singhal Priya | Head of Development | 110 <0.0001% | $157.21 | $17,293 | -9.73% | |
| 2024-09-03 | Sale | Singhal Priya | Head of Development | 431 0.0003% | $204.22 | $88,019 | -27.07% | |
| 2024-04-02 | Sale | Singhal Priya | Head of Development | 93 <0.0001% | $213.09 | $19,817 | -8.11% | |
| 2024-02-22 | Sale | Singhal Priya | Head of Development | 262 0.0002% | $221.23 | $57,962 | -9.78% | |
| 2024-02-16 | Sale | Singhal Priya | Head of Development | 108 <0.0001% | $221.49 | $23,921 | -8.00% | |
| 2024-02-15 | Rowinsky Eric K | director | 455 0.0003% | $222.54 | $101,256 | -9.74% | ||
| 2024-02-12 | Sale | Singhal Priya | Head of Development | 419 0.0003% | $239.45 | $100,330 | -17.50% | |
| 2024-02-02 | Sale | Singhal Priya | Head of Development | 634 0.0004% | $245.93 | $155,920 | -16.35% | |
| 2023-12-11 | Sale | Singhal Priya | Head of Development | 110 <0.0001% | $248.00 | $27,280 | -11.89% | |
| 2023-09-05 | Sale | Singhal Priya | Head of Development | 431 0.0003% | $269.43 | $116,124 | -14.37% | |
| 2023-07-03 | Sale | Singhal Priya | Head of Development | 81 <0.0001% | $282.87 | $22,912 | -15.65% | |
| 2023-04-28 | Sale | Gregory Ginger | EVP, Human Resources | 2,681 0.0018% | $300.00 | $804,300 | -15.75% | |
| 2023-04-04 | Sale | Singhal Priya | Head of Development | 91 <0.0001% | $277.11 | $25,217 | -5.93% | |
| 2023-03-28 | Sale | Singhal Priya | Head of Development | 568 0.0004% | $270.06 | $153,394 | -3.60% | |
| 2022-11-14 | Sale | Gregory Ginger | EVP, Human Resources | 5,610 0.0039% | $300.11 | $1.68M | -7.22% | |
| 2022-10-27 | Sale | ALEXANDER SUSAN H | EVP Chief Legal Off & Corp Sec | 5,532 0.0039% | $280.70 | $1.55M | +0.80% | |
| 2021-06-07 | Sale | Sandrock Alfred | Head of Research & Development | 7,672 0.0057% | $440.00 | $3.38M | -39.39% | |
| 2021-06-07 | Sale | Guindo Chirfi | Head of Glob Prod Strat & Com | 3,087 0.0023% | $440.00 | $1.36M | -39.39% |
Insider Historical Profitability
| DORSA CAROLINE | director | 27842 0.019% | $3.43M | 9 | 2 | +28.27% |
| SHERWIN STEPHEN A | director | 11318 0.0077% | $1.39M | 0 | 9 | |
| Singhal Priya | Head of Development | 5426 0.0037% | $668,324.80 | 0 | 12 | |
| DENNER ALEXANDER J | director | 643000 0.4388% | $79.19M | 12 | 4 | +0.39% |
| SHARP PHILIP A | director | 468033 0.3194% | $57.64M | 0 | 6 | |
| HANNA NABIL | EVP Discovery Research | 450905 0.3077% | $55.53M | 0 | 4 | |
| MULLEN JAMES C | CEO & President | 131149 0.0895% | $16.15M | 0 | 54 | |
| PICKETT CECIL B | President, R & D | 116135 0.0793% | $14.3M | 0 | 4 | |
| ROHN WILLIAM R | Chief Operating Officer | 65462 0.0447% | $8.06M | 0 | 13 | |
| SCANGOS GEORGE A | Chief Executive Officer | 54779 0.0374% | $6.75M | 0 | 47 | |
| BELZER ALAN | director | 40250 0.0275% | $4.96M | 0 | 3 | |
| ALEXANDER SUSAN H | EVP Chief Legal Off & Corp Sec | 39396 0.0269% | $4.85M | 0 | 16 | |
| Vounatsos Michel | Chief Executive Officer | 34810 0.0238% | $4.29M | 5 | 0 | +8.6% |
| Hamm Robert A | Chief Operating Officer | 27212 0.0186% | $3.35M | 0 | 14 | |
| HASLER HANS PETER | Chief Operating Officer | 26858 0.0183% | $3.31M | 0 | 11 | |
| Hasnain Faheem | EVP, Oncology/Rheumatology SBU | 25454 0.0174% | $3.13M | 0 | 4 | |
| Cox John | EVP Pharmaceutical Oper & Tech | 25567 0.0174% | $3.15M | 0 | 11 | |
| WIGGINS MARK C | EVP Corp. and Bus. Dev. | 22780 0.0155% | $2.81M | 0 | 32 | |
| MATSUI CONNIE | EVP, Corp. Strategy and Comm. | 22571 0.0154% | $2.78M | 0 | 9 | |
| Rowinsky Eric K | director | 20629 0.0141% | $2.54M | 1 | 6 | <0.0001% |
| KELLOGG PETER N | EVP, Finance and CFO | 18966 0.0129% | $2.34M | 0 | 3 | |
| DUNN JOHN MICHAEL | EVP, New Ventures | 18712 0.0128% | $2.3M | 0 | 16 | |
| PANGIA ROBERT W | director | 18587 0.0127% | $2.29M | 0 | 20 | |
| YOUNG WILLIAM | director | 18509 0.0126% | $2.28M | 0 | 5 | |
| Kowolenko Michael | SVP, Pharm Ops & Technology | 18124 0.0124% | $2.23M | 0 | 4 | |
| ADELMAN BURT A | EVP, Portfolio Strategy | 12769 0.0087% | $1.57M | 0 | 21 | |
| WILLIAMS DOUGLAS E | EVP Research & Development | 11817 0.0081% | $1.46M | 0 | 3 | |
| MacLean Michael F | SVP, Chief Accounting Officer | 11634 0.0079% | $1.43M | 0 | 7 | |
| Clancy Paul J | Executive VP and CFO | 10813 0.0074% | $1.33M | 0 | 14 | |
| SCHNEIER CRAIG ERIC | EVP, HR, Public Affairs & Comm | 10201 0.007% | $1.26M | 0 | 41 | |
| Sandrock Alfred | Head of Research & Development | 10169 0.0069% | $1.25M | 0 | 25 | |
| ROSS BRUCE | director | 9900 0.0068% | $1.22M | 0 | 12 | |
| Pawlicki Raymond | SVP, Chief Information Officer | 8710 0.0059% | $1.07M | 0 | 5 | |
| Gregory Ginger | EVP, Human Resources | 8483 0.0058% | $1.04M | 0 | 2 | |
| LEAMING NANCY | director | 7660 0.0052% | $943,405.60 | 0 | 11 | |
| Posner Brian S | director | 7400 0.0051% | $911,384.00 | 0 | 14 | |
| Karaboutis Adriana | EVP, Tech, Bus. Sol & Corp Aff | 7360 0.005% | $906,457.60 | 0 | 7 | |
| RODRIGUEZ EDWARD | VP and Controller | 7100 0.0048% | $874,436.00 | 0 | 2 | |
| PAPADOPOULOS STELIOS | director | 5000 0.0034% | $615,800.00 | 1 | 2 | <0.0001% |
| Holtzman Steven H | EVP Corporate Development | 4321 0.0029% | $532,174.36 | 0 | 9 | |
| Ehlers Michael D | EVP, Research and Development | 4281 0.0029% | $527,269.02 | 0 | 1 | |
| Gagnon Robert E. | Vice President, Finance | 3999 0.0027% | $492,516.84 | 0 | 15 | |
| GLASSBERG ALAN | director | 3550 0.0024% | $437,218.00 | 0 | 8 | |
| Kingsley Stuart A | EVP, Global Comm. Operations | 3511 0.0024% | $432,414.76 | 0 | 3 | |
| SCHENK LYNN | director | 3100 0.0021% | $381,796.00 | 0 | 11 | |
| Guindo Chirfi | Head of Glob Prod Strat & Com | 2919 0.002% | $359,504.04 | 0 | 1 | |
| Mantas Jesus B | director | 2943 0.002% | $362,459.88 | 1 | 0 | +1.75% |
| Koppel Adam | EVP, Strategy and Bus. Dev. | 2402 0.0016% | $295,844.15 | 0 | 2 | |
| Mulligan Richard | director | 2020 0.0014% | $248,783.20 | 0 | 3 | |
| KELLER THOMAS F | director | 1250 0.0009% | $153,950.00 | 0 | 9 | |
| Artavanis-Tsakonas Spyridon | SVP, Chief Scientific Officer | 352 0.0002% | $43,354.17 | 0 | 1 | |
| RASTETTER WILLIAM H | Executive Chairman | 0 0% | $0 | 0 | 4 | |
| BUCKNUM THOMAS J | EVP and General Counsel | 0 0% | $0 | 0 | 4 | |
| GOOD MARY L | director | 0 0% | $0 | 0 | 5 | |
| Gilman Michael | EVP - Research | 0 0% | $0 | 0 | 3 | |
| Granata Francesco | EVP Global Commercial Operatio | 0 0% | $0 | 0 | 1 | |
| DiPietro Kenneth | EVP Human Resources | 0 0% | $0 | 0 | 6 |
Historical Insider Profitability vs. Competitors
Biogen Inc. (BIIB) | $364,217,072 | 28 | 9.11% | $18.05B |
$6,077,160 | 24 | 3.21% | $357.72B | |
$1,922,773,492 | 23 | 18.03% | $707.07B | |
$28,542,809 | 19 | 26.41% | $332.08B | |
$23,029,445 | 18 | 9.33% | $94.81B | |
$1,995,978 | 16 | -0.53% | $130.02B | |
$17,024,470 | 16 | 4.31% | $192.42B | |
$3,170,734 | 10 | 3.98% | $145.42B | |
$3,933,798 | 8 | 12.50% | $126.17B | |
$252,679 | 2 | 0.47% | $2.19B |
BIIB Institutional Investors: Active Positions
| Increased Positions | 435 | +45.84% | 14M | +10.77% |
| Decreased Positions | 402 | -42.36% | 16M | -11.75% |
| New Positions | 118 | New | 3M | New |
| Sold Out Positions | 119 | Sold Out | 3M | Sold Out |
| Total Postitions | 982 | +3.48% | 131M | -0.98% |
BIIB Ownership Change vs Market
Institutional Investor Ownership
| Vanguard Group Inc | $2.07M | 11.39% | 16.75M | +70,368 | +0.42% | 2024-12-31 |
| Primecap Management Co/Ca/ | $1.98M | 10.92% | 16.05M | -268,870 | -1.65% | 2024-12-31 |
| Blackrock, Inc. | $1.88M | 10.35% | 15.21M | -262,674 | -1.7% | 2025-03-31 |
| State Street Corp | $913,906.00 | 5.03% | 7.4M | +53,288 | +0.73% | 2024-12-31 |
| Wellington Management Group Llp | $609,092.00 | 3.35% | 4.93M | -200,470 | -3.91% | 2024-12-31 |
| Geode Capital Management, Llc | $456,502.00 | 2.51% | 3.7M | +82,456 | +2.28% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $382,917.00 | 2.11% | 3.1M | -1M | -27.17% | 2024-12-31 |
| Pacer Advisors, Inc. | $329,520.00 | 1.82% | 2.67M | +3M | +13,574.74% | 2024-12-31 |
| Norges Bank | $287,232.00 | 1.58% | 2.33M | +246,454 | +11.86% | 2024-12-31 |
| Invesco Ltd. | $262,972.00 | 1.45% | 2.13M | +499,074 | +30.62% | 2024-12-31 |